Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor α-neutralizing agents

Arthritis and Rheumatism

Volumn 48, Issue 2, 2003, Pages 319-324

  Slifman, Nancy R ^a   Gershon, Sharon K ^a   Lee, Jong Hoon ^a   Edwards, Evelyne T ^a   Braun, M Miles ^a,b  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ANTITUSSIVE AGENT; AZATHIOPRINE; CAPTOPRIL; CELECOXIB; DIGOXIN; DIPHENHYDRAMINE PLUS PARACETAMOL; ETANERCEPT; FLECAINIDE; FOLIC ACID; FUROSEMIDE; HYDROCODONE BITARTRATE PLUS PARACETAMOL; HYDROXYCHLOROQUINE; INDAPAMIDE; INFLIXIMAB; INSULIN; LEVOTHYROXINE; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NAPROXEN; NORTRIPTYLINE; PREDNISONE; SPIRONOLACTONE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNCLASSIFIED DRUG; UNINDEXED DRUG; WARFARIN;

ADOLESCENT; ADULT; AGED; ARTICLE; BLOOD DISEASE; CHOLECYSTITIS; CLINICAL ARTICLE; CROHN DISEASE; DRUG SURVEILLANCE PROGRAM; FEMALE; FOOD AND DRUG ADMINISTRATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATORY DISEASE; LISTERIA MONOCYTOGENES; LISTERIOSIS; MALE; MENINGITIS; OPPORTUNISTIC INFECTION; PATHOGENESIS; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; RHEUMATOID ARTHRITIS; SEPSIS;

ADOLESCENT; ADULT; ADVERSE DRUG REACTION REPORTING SYSTEMS; AGED; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; FEMALE; HUMANS; IMMUNOGLOBULIN G; LISTERIA INFECTIONS; MALE; MIDDLE AGED; RECEPTORS, TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0037331223     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.10758     Document Type: Article

References (41)

1. Bazzoni F, Beutler B. The tumor necrosis factor ligand and receptor families. N Engl J Med 1996;334:1717-25.
2. O'Dell JR. Anticytokine therapy: a new era in the treatment of rheumatoid arthritis? [editorial] N Engl J Med 1999;340:310-2.
3. Choy EHS, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 2001;344:907-16.
4. Schluter D, Deckert M. The divergent role of tumor necrosis factor receptors in infectious diseases. Microbes Infect 2000;2:1285-92.
5. Unanue ER. Studies in listeriosis show the strong symbiosis between the innate cellular system and the T-cell response. Immunol Rev 1997;158:11-25.
6. Edelson BT, Unanue ER. Immunity to Listeria infection. Curr Opin Immunol 2000;12:425-31.
7. Nakane A, Minagawa T, Kato K. Endogenous tumor necrosis factor (cachectin) is essential to host resistance against Listeria monocytogenes infection. Infect Immun 1988;56:2563-9.
8. Havell EA. Evidence that tumor necrosis factor has an important role in antibacterial resistance. J Immunol 1989;143:2894-9.
9. Pfeffer K, Matsuyama T, Kundig TM, Wakeham A, Kishihara K, Shahinian A, et al. Mice deficient for the 55 kd tumor necrosis factor receptor are resistant to endotoxic shock, yet succumb to L. monocytogenes infection. Cell 1993;73:457-67.
10. Rothe J, Lesslauer W, Lotscher H, Lang Y, Koebel P, Kontgen F, et al. Mice lacking the tumour necrosis factor receptor 1 are resistant to TNF-mediated toxicity but highly susceptible to infection by Listeria monocytogenes. Nature 1993;364:798-802.
11. Van Furth R, van Zwet TL, Buisman AM, van Dissel JT. Anti-tumor necrosis factor antibodies inhibit the influx of granulocytes and monocytes into an inflammatory exudate and enhance the growth of Listeria monocytogenes in various organs. J Infect Dis 1994;170:234-7.
12. Saxne T, Palladino MA Jr, Heinegard D, Talal N, Wollheim FA. Detection of tumor necrosis factor α but not tumor necrosis factor β in rheumatoid arthritis synovial fluid and serum. Arthritis Rheum 1988;31:1041-5.
13. Maini RN, Taylor PC. Anti-cytokine therapy for rheumatoid arthritis. Annu Rev Med 2000;51:207-29.
14. Murch SH, Braegger CP, Walker-Smith JA, MacDonald TT. Location of tumour necrosis factor alpha by immunohistochemistry in chronic inflammatory bowel disease. Gut 1993;34:1705-9.
15. Plevy SE, Landers CJ, Prehn J, Carramanzana NM, Deem RL, Shealy D, et al. A role for TNF-alpha and mucosal T helper-1 cytokines in the pathogenesis of Crohn's disease. J Immunol 1997;159:6276-82.
16. Van Deventer SJH. Tumor necrosis factor and Crohn's disease. Gut 1997;40:443-8.
17. Lugering A, Schmidt M, Lugering N, Pauels H-G, Domschke W, Kucharzik T. Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway. Gastroenterology 2001;121:1145-57.
18. Ten Hove T, van Montfrans C, Peppelenbosch MP, van Deventer SJH. Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease. Gut 2002;50:206-11.
19. Wood AJJ. Thrombotic thrombocytopenic purpura and clopidogrel: a need for new approaches to drug safety [editorial]. N Engl J Med 2000;342:1824-6.
20. CDC FoodNet annual reports (2000). Accessed October 2, 2002. URL: www.cdc.gov/foodnet/annuals.htm.
21. Slutsker L, Schuchat A. Listeriosis in humans. In: Ryser ET, Marth EH, editors. Listeria, listeriosis, and food safety. 2nd ed. New York: Marcel Dekker; 1999. p. 75-95.
22. Lorber B. Listeria monocytogenes. In: Mandell GL, Bennett JE, Dolin R, editors. Mandell, Douglas, and Bennett's principles and practice of infectious diseases. 5th ed. Vol. 2. Philadelphia: Churchill Livingstone; 2000. p. 2208-15.
23. Schuchat A, Deaver KA, Wenger JD, Plikaytis BD, Mascola L, Pinner RW, et al. Role of foods in sporadic listeriosis. I. Casecontrol study of dietary risk factors. JAMA 1992;267:2041-5.
24. Skogberg K, Syrjanen J, Jahkola M, Renkonen O-V, Paavonen J, Ahonen J, et al. Clinical presentation and outcome of listeriosis in patients with and without immunosuppressive therapy. Clin Infect Dis 1992;14:815-21.
25. Wing EJ, Gregory SH. Listeria monocytogenes: clinical and experimental update. J Infect Dis 2002;185:S18-S24.
26. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001;345:1098-1104.
27. Fisher CJ Jr, Agosti JM, Opal SM, Lowry SF, Balk RA, Sadoff JC, et al. Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. N Engl J Med 1996;334:1697-702.
28. Lee J-H, Slifman NR, Gershon SK, Edwards ET, Schwieterman WD, Siegel JN, et al. Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor α antagonists infliximab and etanercept. Arthritis Rheum 2002;46:2565-70.
29. Martinez ON, Noiseux CR, Martin JAC, Lara VG, Maranon HGUG. Reactivation tuberculosis in a patient with anti-TNF-α treatment [letter]. Am J Gastroenterol 2001;96:1665-6.
30. Morelli J, Wilson FA. Does administration of infliximab increase susceptibility to listeriosis? [letter] Am J Gastroenterol 2000;95:841-2.
31. Kamath BM, Mamula P, Baldassano RN, Markowitz JE. Listeria meningitis after treatment with infliximab. J Pediatr Gastroenterol Nutr 2002;34:410-2.
32. Gluck T, Linde H-J, Scholmerich J, Muller-Ladner U, Fiehn C, Bohland P. Anti-tumor necrosis factor therapy and Listeria monocytogenes infection: report of two cases [letter]. Arthritis Rheum 2002;46:2255-7.
33. Warris A, Bjorneklett A, Gaustad P. Invasive pulmonary aspergillosis associated with infliximab therapy [letter]. N Engl J Med 2001;344:1099-100.
34. Singh S, Rau N, Harris H, Cohen LB. Cutaneous nocardiosis complicating Crohn's disease management with infliximab [abstract]. Am J Gastroenterol 2001;96 Suppl:S308.
35. Baghai M, Osmon DR, Wolk DM, Wold LE, Haidukewych GJ, Matteson EL. Fatal sepsis in a patient with rheumatoid arthritis treated with etanercept. Mayo Clin Proc 2001;76:653-6.
36. Chan ATY, Cleeve V, Daymond TJ. Necrotising fasciitis in a patient receiving infliximab for rheumatoid arthritis. Postgrad Med J 2002;78:47-8.
37. Ritz MA, Jost R. Severe pneumococcal pneumonia following treatment with infliximab for Crohn's disease [letter]. Inflamm Bowel Dis 2001;7:327.
38. Keenan GF, Schaible TF, Boscia JA. Invasive pulmonary aspergillosis associated with infliximab therapy [reply]. N Engl J Med 2001;344:1100.
39. Important drug warning (Centocor). Accessed October 2, 2002. URL: www.fda.gov/medwatch/safety/2001/safety01.htm#remica.
40. Listeriosis. Accessed October 2, 2002. URL: www.cdc.gov/ncidod/dbmd/diseaseinfo/listeriosis_g.htm#.
41. Tappero JW, Schuchat A, Deaver KA, Mascola L, Wenger JD. Reduction in the incidence of human listeriosis in the United States: effectiveness of prevention efforts? JAMA 1995;273:1118-22.